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Objective(s). Bisphosphonates are frequently used worldwide mostly in osteoporosis and skeletal bone metastases. However,
a serious side-effect is bisphosphonate related osteonecrosis of the jaws (BRONJ). The mechanism behind BRONJ remains
unclear. In literature several origins are suggested. Presence of the teeth in the jaws may play an important role. Therefore in
this study 45 patients were analyzed retrospectively.
Study design. Files of 45 patients with a diagnosis of BRONJ were analyzed, meaning clinical features, bisphosphonate use,
dental history including luxating moment and (previous) treatment.
Results. In 97.5% (n ¼ 44) a certain or presumable dental focus, such as extractions, a previous dental treatment or prosthesis
complaints were found as initiating factor of BRONJ.
Conclusion. In contrast to findings in literature, in our group of patients a dental focus was found in 44 of 45 cases. This
implies a dentoalveolar start of BRONJ with subsequent spreading into the jaws in nearly all cases. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2013;116:287-292)Bisphosphonates are frequently used worldwide. There
are several indications to prescribe bisphosphonates.
The most important indications are osteoporosis and
skeletal bone metastases in malignancies. Bisphospho-
nates decrease the function of osteoclasts and hence
bone resorption. They stabilize the osteoporotic
process, further growth and metastasizing in bone and
improve complaints such as pain.
However, the use of bisphosphonates may have side
effects. Most frequently described are gastrointestinal
effects. In 2003 the ﬁrst case of osteonecrosis of the jaw
was reported.1 According to the deﬁnition of BRONJ
given by the American Association of Oral and Maxil-
lofacial Surgeons (AAOMS) patients may be considered
to have BRONJ if 3 characteristics are present: current
or previous treatment with a bisphosphonate, exposed,
necrotic bone in the maxillofacial region that persisted
for more than 8 weeks, no history of radiation therapy to
the jaws. In addition, different stages of the disease
according to signs of inﬂammation2 were developed
(Table I).
The precise mechanism of BRONJ still remains
unclear. In the literature BRONJ is said to be resistant
to therapy and may lead to serious loss of bone. Many
authors including large dental associations as the
AAOMS,3 the American Dental Association4,5 and the
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Open access under CC BY-NC-ND license.advise a conservative treatment, based on the fact that
bisphosphonate use causes systemic changes in bone
and may start spontaneously. However, since no
bisphosphonate related osteonecrosis of other bones has
been reported in the literature, it seems that the presence
of teeth in the jaw plays an important role.
In literature there is no deﬁnition of the minimum
duration of the use of oral bisphosphonates for devel-
oping BRONJ. According to the AAOMS3 the risk for
developing BRONJ increases when the duration of oral
bisphosphonate therapy exceeds 36 months. Marx7 and
other authors8,9 include patients with a duration of oral
use of at least 247,9 and even 128 months. For the oral
use of bisphosphonates in our group a minimum of
24 months was taken. For the use of intravenous
bisphosphonates a minimum use of 12 months was
taken.
In this study a distinction was made between spon-
taneous and dental causes of BRONJ. If the latter is the
case, then treatment results could possibly be improved
by using treatment used for chronic suppurative oste-
omyelitis (CSO), which nearly always has a dental
cause. In CSO a thorough surgical intervention with
primary closure in layers and an antibiotic protocol
leads to good results and healing of the defect.10 In the
treatment of BRONJ, recent literature using this type of
treatment shows also acceptable results.Statement of Clinical Relevance
The origin of bisphosphonate related osteonecrosis
of the jaws is said to be spontaneous. This report
suggests a dental origin. This knowledge may
determine further treatment.
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Table I. Staging of bisphosphonate-related osteonec-
rosis of the jaw
At risk category
No apparent exposed/necrotic bone in patients
who have been treated with either oral or IV
bisphosphonates
Stage 0 Nonspeciﬁc clinical ﬁndings and symptoms such
as jaw pain or osteosclerosis but no clinical
evidence of exposed bone
Stage 1 Exposed/necrotic bone in patients who are
asymptomatic and have no evidence of
infection
Stage 2 Exposed/necrotic bone associated with infection
as evidenced by pain and erythema in the
region of the exposed bone with or without
purulent drainage
Stage 3 Exposed/necrotic bone in patients with pain,
infection, and one or more of the following:
pathologic fracture, extra-oral ﬁstula, or
osteolysis extending to the inferior border or
sinus ﬂoor
Fig. 1. Indications of bisphosphonate use in percentages.
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The ﬁles of 51 patients using bisphosphonates and with
exposed bone of the jaws were reviewed. All patients were
treated and followed in the Department of Oral and
Maxillofacial Surgery of the Leiden University Medical
Center. All patients were diagnosed with BRONJ accord-
ing to the AAOMS deﬁnition. To be included into this
study patients aminimumuse of bisphosphonate for at least
12 months intravenously or 24 months orally. Considering
these criteria 45 patients were included in this study.
Patient characteristics, bisphosphonate use, clinical
features, dental history, and (previous) treatment were
studied. Patients with a combination of oral and intra-
venous bisphosphonates were counted into the intra-
venous group.
In order to analyze the luxating moments of BRONJ,
all initiating factors were categorized into 4 groups:
a certain dental focus, a presumable dental focus,
spontaneous and unknown.
A certain dental focus was deﬁned as a recent dental
procedure as an extraction, removal of retained roots,
placing of implants, an apical inﬂammation or clear pre-
existent periodontal problems in the region of the BRONJ.
A presumable dental focus was deﬁned as an
elevated mylohyoid ridge, a clear knife-edge ridge and
(gingival) trauma caused by non-ﬁtting dentures.
Spontaneous exposed bone was deﬁned as no previous
dental history, no previous therapy, no previous trauma,
or no previous existing complaints related to dentures.
Patients were categorized as unknown dental focus
when the previous history was unclear or not traceable.
RESULTS
Patient characteristics
Most patients suffered from malignancies 57.8%
(n ¼ 26). From this group 61.6% (n ¼ 16) had(metastasized) breast cancer, 23.1% (n¼ 6) had multiple
myeloma, 11.5% (n ¼ 3) had prostate cancer and 3.8%
(n ¼ 1) had lung cancer. One patient (2.2%) had Paget’s
disease. Osteoporosis counted for 40.0% (n¼ 18) of the
indications for bisphosphonate treatment (Figure 1).
The clinical characteristics of the 45 patients are
listed in Table III. A total of 80.0% (n ¼ 36) was
female, 20.0% (n ¼ 9) was male. Age varied from 45 to
84 with a mean of 66.1 years.
From 45 patients 77.8% (n ¼ 35) had BRONJ of the
mandible, 15.5% (n ¼ 7) of the maxilla and 6.7%
(n ¼ 3) of both jaws.
Oral bisphoshonates were used in 16 cases (35.6%)
with a minimum of 24 months and a maximum of
132 months and a mean of 57.3 months. Intravenous
bisphosphonates were used in 29 cases (64.4%) with
a minimum of 12 months and a maximum of
108 months and a mean of 30.8 months.
Pamidronate (Aredia; Novartis, East Hanover, NJ,
USA) was the bisphosphonate most frequently used
intravenously. In the oral group Alendronate (Fosamax;
Merck & Co., Whitehouse Station, NJ, USA) was most
frequently used. There were 9 patients who had used both
oral and intravenous bisphosphonates (Table II). These
patients were counted in the intravenous group, for
intravenous bisphosphonates are far more potent than
bisphosphonates taken orally and therefore more at risk
for BRONJ.
Initiating factors
In Table II the luxating moments are listed. In 97.8%
(n ¼ 44) of the patients a dental focus was found. In
80.0% (n ¼ 36) of the cases this was a certain dental
focus. In 20.0% (n ¼ 9) of the cases the dental focus
was presumable according to the deﬁnitions listed
earlier. In one case (2.2%) we were not able to trace
a luxating moment, despite retracing the dental history.
Case number 16 presented with a ﬁstulating swelling
underneath an ill-ﬁtting denture. No patients were
found with a history of spontaneous exposed bone.DISCUSSION
In literature many authors show a high percentage of
spontaneous causes of BRONJ. Recently there is
a rising percentage of dental causes of BRONJ. Since
the cause of BRONJ may inﬂuence the treatment
Table II. Features patients, indication and bisphosphonate use
No. Age Sex Indication Bisphosphonate
Duration use
(months)
Administration
route Location Luxating moment Category
1 83 F OP Pam 84 OR Mandible Preprosthetic surgery Presumable
2 84 F Paget’s disease Pam 24 OR Both Extraction Certain
3 46 M OP Pam, Al 132; 12 OR Mandible Extraction Certain
4 84 F OP Pam 48 OR Maxilla Extraction Certain
5 88 F OP Pam, Al 24 OR Mandible Extraction Certain
6 77 F OP Pam, Al 72; 60 B Both Extraction Certain
7 67 F OP Et, Al 9; 30 OR Mandible Implants Certain
8 84 F Mult Myel Pam 12 IV Mandible Implants Certain
9 45 F Breast ca Clo 29 OR Mandible Periodontal disease Certain
10 59 F Breast ca Pam 36 IV Mandible Extraction Certain
11 54 F OP Pam 108 IV Mandible Pressure sore Presumable
12 65 F Breast ca Pam 53 IV Mandible Extraction Certain
13 82 F Mult Myel Et, Pam 1; 72 B Both Extraction Certain
14 83 F OP Pam 96 IV Mandible Extraction Certain
15 67 M Mult Myel Zol, Pam, Al 12; 10; 22 B Mandible Extraction Certain
16 73 F OP Al 46 OR Mandible Extraction Unclear
17 75 F OP Pam, Al 84; 36 OR Mandible Presumable extra Presumable
18 53 F Breast ca Pam 24 IV Mandible Extraction Certain
19 72 F OP Pam 24 IV Mandible Extraction Certain
20 76 M OP Al 52 OR Mandible Mylohyoid ridge Presumable
21 80 F Breast ca Pam 54 IV Mandible Unknown Unclear
22 57 F Mult Myel Pam 83 IV Mandible Knife-edge ridge Presumable
23 66 F Breast ca Pam 24 IV Mandible Extraction Certain
24 52 F Breast ca Pam 48 IV Mandible Extraction Certain
25 60 F Breast ca Pam 24 IV Maxilla Extraction Certain
26 51 F Breast ca Pam 45 IV Mandible Pressure sore Presumable
27 59 M Prostate ca Pam, Zol 24; 26 IV Mandible Dental treatment Presumable
28 84 M Mult Myel Pam 24 IV Maxilla Extraction Certain
29 47 F OP Al 24 OR Mandible Apical granuloma Certain
30 68 M Lung ca Al 31 OR Mandible Pressure sore Presumable
31 61 F Breast ca Pam 24 IV Maxilla Implants Certain
32 55 F Breast ca Pam 24 IV Mandible Extraction Certain
33 70 F OP Ris 24 OR Mandible Extraction Certain
34 65 M Prostate ca Zol 36 IV Mandible Extraction Certain
35 70 F OP Al 120 OR Mandible Extraction Certain
36 67 F OP Al 84 OR Mandible Implants Certain
37 60 M Prostate ca Zol 12 IV Mandible Extraction Certain
38 54 F Breast ca Pam 38 IV Mandible Extraction Certain
39 52 F Breast ca Pam, Iban 12; 44 B Maxilla Implants Certain
40 75 F Breast ca Pam 12 IV Mandible Extraction Certain
41 71 F OP Pam 12 IV Mandible Extraction Certain
42 71 F Breast ca Iban, Zol 48; 12 B Maxilla Extraction Certain
43 56 F Breast ca Pam 38 IV Mandible Extraction Certain
44 75 F OP Al 36 OR Maxilla Implants Certain
45 76 M Mult Myel Pam 18 IV Mandible Extraction Certain
F, female; M, male; OP, osteoporosis; Mult Meyl, multiple myeloma; ca, cancer; Al, Alendronic acid (Fosamax); Pam, Pamidronic acid; Ris,
risedronate (Actonel; Procter & Gamble, Cincinnati, OH, USA); Et, etidronate (Didronel; Procter & Gamble); Zol, Zolendronic Acid (Zometa;
Novartis); Iban, Ibandronate (Boniva; Roche, Basel, Switzerland); OR, orally; IV, intravenously; B, both orally and intravenously.
OOOO ORIGINAL ARTICLE
Volume 116, Number 3 Pichardo and van Merkesteyn 289choices we studied all possible initiating factors of
BRONJ. They were categorized in: “a certain dental
focus,” “a presumable dental focus,” “spontaneous,”
and “an unknown dental focus” in order to give us more
insight in the mechanisms of the etiology of BRONJ. In
none of the patients we found a convincing spontaneous
origin. In 97.8% of the patients a certain or presumable
dental focus was found. In our series as well as in the
literature, there seems to be no difference between thecauses in the intravenous and the oral bisphosphonate
group.
Our ﬁndings correspond with those of a few authors
in the literature.11-19 Most of the authors report a higher
percentages of spontaneous cases (Table III), varying
from 14.1% to 60%.2,20-40 This may be due to the fact
that it is difﬁcult to establish the initiating factor in
some patients. For example, in our series 1 patient
(2.1% classiﬁed as ‘unknown dental focus’) presented
Table III. Overview literature origin BRONJ
Author Year No. of patients Administration route Spontaneous (%) Dental focus (%)
Badros20 2008 97 IV 53 47
Bagan21 2006 20 IV 55 45
Bamias11 2005 17 IV 11.8 88.2
Bedogni12 2008 11 IV 18.1 81.9
Boonyapakorn22 2007 22 IV 23 77
Dimopoulos13 2006 15 IV 13.3 86.7
Durie26 2005 152 IV 19-31 69-81
Estilo23 2008 35 IV 40 51.4
Ficarra14 2005 9 IV 0 100
Filleul24 2010 2400 B 26 74
Kos15 2009 34 IV 0 91.2
Lugassy25 2004 3 IV 66.7 33.3
Maerevoet26 2005 9 IV 1 0
Manfredi9 2011 25 B 28 72
Marx7 2005 119 B 25.2 74.8
Marx27 2007 30 OR 50 50
Mavrokokki16 2007 112 B 21 79
Melo17 2005 11 IV 9.1 91.85
Merigo8 2006 29 B 48.3 51.7
Migliorati28 2005 17 IV 60 40
O’Ryan29 2012 30 OR 33.3 66.7
Otto19 2011 66 B 0 100
Pichardo 2013 45 B 0 97.8
Pires30 2005 12 IV 33 67
Purcell and Boyd31 2005 13 B 62 38
Rugierro32 2004 63 B 14.1 86
Saad33 2011 89 IV 35.1 64.9
Then34 2012 29 B 34.5 65.5
Thumbigere-Math35 2012 576 IV 41 59
Vescovi36 2010 567 B 31.7 68.3
Vescovi37 2012 151 B 29.1 70.9
Wang38 2003 3 IV 33.3 66.7
Watters39 2012 109 IV 33.9 59.7
Woo40 2007 368 B 40 60
Zarychanski18 2006 12 IV 17 83
IV, intravenously; OR, orally; B, both orally and intravenously.
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denture, making gingival trauma due to trauma likely.
The question remains whether the swelling caused the
denture not to ﬁt, or the ill-ﬁtting denture caused
gingival trauma and hence an inﬂammation and
swelling. In this case the information to make it ‘certain
or presumable’ could not be traced.
In the category ‘certain dental origin’ patients had
procedures, which created a direct port d’entree for
microorganisms to enter the jaw. This is in line with
the pathogenesis of osteomyelitis of the jaw with
a common dentoalveolar start of the disease and
subsequent spreading throughout the jaw. In these cases
early treatment gives good results.41-44 When the
pathogenesis of BRONJ resembles the pathogenesis of
chronic osteomyelitis, early treatment according to the
principles of the treatment of osteomyelitis should give
better results than those reported in the literature of
BRONJ so far. In fact several authors as Alons,41
Williamson,42 Wilde,43 and Voss44 already have shownto be able to cure a high percentages BRONJ, thus
strongly suggesting a pathogenesis of the disease
similar to the “ordinary” osteomyelitis. All patients of
this series were treated according to the protocol
reported by Alons.40
In the category ‘presumable dental origin’ several
patients were found with prosthetic problems leading to
trauma to the overlying soft tissues thus presumably
leading to a BRONJ. Possibly many of the ‘sponta-
neous’ cases found in the literature belong to this
category.2,20-40
In conclusion a spontaneous origin of BRONJ has
not been found in this series of patients. In 44 patients
(97.8%) a dental origin was found. This may lead to
a treatment approach as in chronic osteomyelitis with
more aggressive surgical intervention with better treat-
ment results, which has already been suggested in the
literature.
However, this conclusion is based on a relatively
small, retrospective study. Further research is mandatory.
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